An RB-1 Loss of Function Gene Signature as a Tool to Predict Response to Neoadjuvant Chemotherapy Plus Anti-Her2 Agents: A Substudy of the NeoALTTO Trial (BIG 1-06)
Therapeutic Advances in Medical Oncology - United States
doi 10.1177/1758835919891608
Full Text
Open PDFAbstract
Available in full text
Categories
Date
January 1, 2019
Authors
Publisher
SAGE Publications